Literature DB >> 16543687

Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity.

Tatsuya Kanto1, Norio Hayashi.   

Abstract

Hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease worldwide. The critical role of innate as well as adaptive immunity has been reported in HCV persistence and liver injury. In the early phase of acute infection, HCV continues to replicate in the liver, suggesting the HCV capability of inhibiting innate immunity. The sustained, vigorous and multiepitope-specific CD4+ and CD8+ T cell responses are essential for spontaneous HCV clearance. HCV-specific CD8+ T cells are primary elements for HCV clearance by inducing hepatocyte apoptosis, in which Fas/CD95 is fundamentally involved. However, once HCV persistency develops, HCV utilizes multifaceted arms to subvert various immune effectors. During IFNalpha-based therapy, the enhancement of HCV-specific CD4+ T cell response followed by HCV eradication has been reported, however, it remains obscure whether the therapeutic HCV clearance is able to restore the durable immune competency to HCV. Further investigation is still warranted to establish the means to direct HCV-specific immune responses in the desired way.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543687     DOI: 10.2169/internalmedicine.45.1530

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  31 in total

1.  Relationship between the pathogenesis of sarcoidosis and hepatitis C.

Authors:  Sevtap Sipahi Demirkok
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

Review 2.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

Review 3.  Macrophages in hepatitis B and hepatitis C virus infections.

Authors:  Mathis Heydtmann
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

4.  Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C.

Authors:  Kuo-Chih Tseng; Yun-Che Ho; Yu-Hsi Hsieh; Ning-Sheng Lai; Zhi-Hong Wen; Chin Li; Shu-Fen Wu
Journal:  J Gastroenterol       Date:  2012-02-28       Impact factor: 7.527

5.  Spontaneous clearance of hepatitis C virus in vertically infected children.

Authors:  Susan Farmand; Stefan Wirth; Helga Löffler; Tanja Woltering; Sybille Kenzel; Elke Lainka; Philipp Henneke
Journal:  Eur J Pediatr       Date:  2011-07-07       Impact factor: 3.183

6.  Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

Authors:  Tatsuya Kanto; Michiyo Inoue; Tsugiko Oze; Masanori Miyazaki; Mitsuru Sakakibara; Naruyasu Kakita; Tokuhiro Matsubara; Koyo Higashitani; Hideki Hagiwara; Sadaharu Iio; Kazuhiro Katayama; Eiji Mita; Akinori Kasahara; Naoki Hiramatsu; Tetsuo Takehara; Norio Hayashi
Journal:  J Gastroenterol       Date:  2011-09-27       Impact factor: 7.527

Review 7.  Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy.

Authors:  Mohamed L Salem; Ahmed El-Badawy
Journal:  World J Hepatol       Date:  2015-10-18

Review 8.  The tug-of-war between dendritic cells and human chronic viruses.

Authors:  Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

Review 9.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

10.  HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice.

Authors:  Michael A Joyce; Kathie-Anne Walters; Sue-Ellen Lamb; Mathew M Yeh; Lin-Fu Zhu; Norman Kneteman; Jason S Doyle; Michael G Katze; D Lorne Tyrrell
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.